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Imaging of implanted hydrogel-based biosystems usually requires indirect labelling of the 
vehicle or cargo, adding complexity and potential risk of altering functionality. Here, for the 
first time, it is reported that incorporating genipin into the design of immunoisolation devices 
can be harnessed for in vivo imaging. Using cell-compatible in situ cross-linking reactions, a 
fast, efficient and non-cytotoxic procedure is shown to maximize fluorescence of 
microcapsules. Moreover, genipin is validated as a quantitative imaging probe by injecting 
increasing doses of microcapsules in the subcutaneous space of mice, obtaining strong, stable 
fluorescence with good linearity of signal to microcapsule dose over several weeks. This 
allows immediate assessment of the actual injected dose and monitoring of its position over 
time, thereby significantly enhancing the efficacy and biosafety of the therapy. These 
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Designing hydrogel technologies for detection by imaging frequently requires modifying the 
hydrogel itself[1, 2] or the cargo,[3] adding complexity to overall design and potentially altering 
mechanical and functional characteristics.[4] We sought to overcome these challenges by 
incorporating a biomaterial with inherent imaging properties into device design. While 
applicable broadly to other areas in biotechnology, in the present study we focus on 
immunoisolation devices consisting of alginate microspheres coated with a semipermeable 
membrane formed by polycations (usually poly-L-Lysine or poly-L-ornithine). The 
membrane protects the encapsulated cell content against immune cell and antibody mediated 
host’s rejection, while allowing the inward diffusion of nutrients and oxygen, and the release 
of bioactive compounds into the surrounding tissue. This approach currently is one of the 
leading strategies to deliver bioactive molecules from immobilized allo- or xenogenic cells.[5, 
6] To date, remarkable outcomes have been obtained in clinical trials for the treatment of 
chronic diseases such as diabetes[7, 8] or cancer.[9, 10]  However, development of a suitable non-
invasive visualization strategy that provides relevant information about implanted 
microcapsules becomes crucial to make the definitive leap to the clinic.[11-13]  
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In this sense, one of the main problems lies in the impossibility to ensure the correct 
administration of the intended dose. This is because, to the best of our knowledge, to date 
there is no tool to immediately assess (quantitatively) the actual injected dose and then 
monitor its position and stability for long periods of time (maintaining a reliable, precise and 
stable signal/dose relation). Alternative imaging strategies, such as reporter genes based on 
luciferase or fluorescence proteins, provide poor information immediately after injection, 
since the hypoxic stress suffered by encapsulated cells during the first days post-implantation 
makes the emitted signal unreliable.[14-16]  
 
Genipin is a natural compound with dual properties that uniquely meet the demand for a 
hydrogel technology detectable through imaging. Strikingly, while benefits of genipin as a 
cross-linker are increasingly appreciated due to its superior biocompatibility, use of natural 
fluorescence from this material has generally been overlooked or considered only 
anecdotally.[17-20] Contrarily, in the nano-scale, genipin-cross-linked globin-PEI 
nanoparticles[21] and genipin cross-linked ovalbumin protein nanoparticles[22] have been 
recently reported as suitable for in vivo imaging. However, described methods are far from 
being applicable to higher scaled cell-laden hydrogels for cell therapies. Indeed, to the best of 
our knowledge, no one has achieved a cytocompatible in situ cross-linking of genipin with 
optimal brightness for in vivo imaging of hydrogel technologies. 
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Here, for the first time, we harness the natural fluorescence of genipin to produce bright, 
quantitative and stable fluorescence for in vivo imaging of cell-laden hydrogel systems. 
Following excitation with red light, genipin emits far-red fluorescence with a broad tail 
extending into the near infra-red spectrum (Figure S1).[21] These wavelengths of light are 
highly favorable for in vivo imaging studies, particularly for hydrogels designed for 
implantation in superficial sites such as subcutaneous, subdermal, or intra-ocular.[23] Our 
results obtained with alginate-poly-L-Lysine immunoisolation devices show that fluorescence 
from genipin meets the need for quantitative imaging of implanted biomaterials. By 
incorporating a biomaterial with inherent imaging properties into device design, this ground-
breaking advance will facilitate clinical translation of a wide range of hydrogel technologies 
for cell-based therapies and tissue engineering.  
 
To obtain a good signal to noise ratio for imaging in vivo, maximizing the fluorescence 
becomes indispensable. Thus, we first optimized the cross-linking procedure of genipin while 
maintaining cell viability using D1 mesenchymal stem cells from Balb/c mice genetically 
engineered to secrete human erythropoietin (D1-MSC-hEPO). We subjected cells 
encapsulated in alginate-poly-L-Lysine (AP) to different combinations of genipin 
concentrations (0.001%, 0.01% and 0.1%) and exposure times (5, 15, 30 and 60 min at room 
temperature) (Figure 1a). For each grouping, we recorded fluorescence intensity of the 
microspheres (Ex: 590 nm; Em: 630 nm) and viability of encapsulated cells. We plotted 
results as a function of these two variables (Figure 1b,c). As a control group, we used cells 
immobilized in non-cross-linked AP microcapsules. Based on these screening assays, we 
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chose the best four conditions where we obtained the highest fluorescence intensities with 
statistically non-significant losses in viability compared with the AP control group (Figure 
1b,c, white points): 0.01% & 30 min < 0.01% & 60 min < 0.1% & 5 min < 0.1% & 15 min (p 
< 0.001 for all comparisons) (Figure S2). 
 
After examining these four protocols in detail (Figure 1d), we chose 0.1% genipin and 5 min 
exposure time as the optimum conditions. Despite rendering lower fluorescence intensity than 
the 0.1% & 15 min combination, the latter showed more internal fluorescence (cross-linked 
cells), so we preferred shorter exposure times to accelerate the coating process and allow 
greater flexibility and safety margin with respect to cell viability. Indeed, most studies to date 
use longer exposure times to genipin (from 30 min to 24 hours),[17, 20, 24] which may limit 
dramatically the applicability of this cross-linking agent for cell microencapsulation purposes. 
Thus, our genipin-meditated cross-linking procedure is fast, efficient and non-cytotoxic, even 
in the presence of cells. 
 
With the aim of maximizing fluorescence signal of the microcapsules, we next added a second 
coating of poly-L-Lysine (PLL) cross-linked with genipin, following the same protocol 
described above (0.1% genipin and 5 min exposure). This process produced genipin-cross-
linked double poly-L-Lysine membranes (GDP) (see 3D morphology in Video S1). As 
intermediate control groups, we also tested AP microcapsules cross-linked with genipin 
(APG), AP with a second PLL coating (APP) and APG microcapsules with an additional 
covering of PLL (APGP) (Figure 2a). All genipin-containing groups developed maximum 
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fluorescence values after 72 – 96 hour periods of incubation (cell culture conditions, after 
exposure to genipin) (Figure 2b), following a first-order reaction (Figure S3). Interestingly, 
we could clearly observe that GDP microcapsules emitted 6-fold higher fluorescence intensity 
than APG and APGP counterparts (p < 0.01 and 0.001, respectively) (Figure 2c,d), probably 
due to increased availability of PLL for cross-linking. This gain in fluorescence is essential 
for maximizing the signal to noise ratio for imaging in vivo. In addition, we easily can 
augment fluorescence intensity by producing smaller size microcapsules. Here, we obtained a 
2.5 fold-increase in fluorescence intensity by just reducing diameter of microcapsules by 33% 
(p < 0.01) (Figure S4). 
 
To exclude any negative effects on cell integrity and function as a consequence of 
incorporating so many variations in microcapsule design, we tested different control groups to 
detect possible problems at any step of the formulation. The protocol for producing GDP 
microcapsules reliably maintained viability of encapsulated cells (Figure 2e,f and Video S2) 
and the capacity of immobilized cells to secrete high rates of therapeutic product, in this case 
human erythropoietin (hEPO) (Figure 2g). All these assays showed no significant differences 
with respect to the AP control group.  
 
Then, we tested performance of GDP microcapsules as a monitoring system for in vivo 
imaging. For such aim, we implanted 50, 100 or 200 µL of GDP microcapsules (Figure 3a) 
into the subcutaneous space of NSG mice. Images obtained with 570 nm excitation and a 
620/20 emission filter exhibited a strong signal with excellent signal to noise ratio for all 
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injections (Figure 3b). Importantly, we also achieved a good linearity of fluorescence 
response to microcapsule dose (R2 = 0.9971) (Figure 3c). We next monitored fluorescence of 
genipin at days 1, 14, 21 and 35 to validate robustness and long-term stability of this non-
invasive visualization strategy (Figure 3d-g). The signal decreased significantly in 50 µL 
dose by day 21 (p < 0.05) but remained relatively stable until day 35. Conversely, 100 and 
200 µL doses showed strong signals that did not differ from the initial point throughout the 
experiment (Figure 3h). Because we injected capsules in PBS, fluorescence signal appears 
modestly less intense and more diffuse on the pseudocolor images of day 1. As PBS resorbs, 
capsules become slightly more localized and fluorescence signal is clearer. Anyhow, 
differences with respect to day 1 are not significative in any case (p > 0.05).  As a control for 
stability of fluorescence, we monitored non-implanted GDP microcapsules from the same 
batch in parallel, showing non-significant differences in signal throughout the experiment 
(Figure 4a). 
 
We further analyzed imaging data to validate genipin as a quantitative imaging probe for 
implanted biomaterials. We first calculated the correlation between administered dose and 
measured fluorescence signal. A scatter plot of dose versus radiant efficiency and analysis of 
the linear regression confirmed the linear correlation (p < 0.001) and the significance of the 
slope obtained from the equation (p < 0.001). However, the goodness of fit demonstrated that 
only 66.14% of the results could be explained by this equation (Figure 4b). Taking into 
account the high R-squared observed when we used mean values, instead of individual values, 
for linear regression (Figure 3c), we hypothesized that low precision arisen from either 
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instrument or human error should be behind the poor fitting. In addition, from mean and SD 
values of the background signal, we estimated the lower limit of detection (LLD) and the 
lower limit of quantification (LLQ), obtaining doses equivalent to 18.6 µL and 59.6 µL for 
each of them respectively (Figure 4b). This means that the significant signal decay observed 
for 50 µL dose over time (Figure 3h) should be considered as non-reliable.  
Considering the proven stability of the fluorescence signal, we calculated the variability 
of measurements taken at different time points for each dose as an indicator of the instrument 
error (repeatability). The lowest dose of 50 µL produced a significantly higher coefficient of 
variation (CV) (46.5%), whereas 100 and 200 µL doses presented 25.7% and 20.8% 
respectively (Figure 4c). These results are comprehensible if we take into account 50 µL dose 
is below the LLQ. Consequently, the high variability of the lowest dose may be the main 
determinant of the poor goodness of fit. By isolating this variability, we also determined the 
human error in the injections of the microcapsules (i.e. dose preparing and administration of 
microcapsules). Thus, in the present study we estimated a CV of 39.8%, 50.8% and 22.2% for 
50, 100 and 200 µL doses respectively (Figure 4d). On the other hand, linear regression 
analysis of the scatter plot for expected versus measured values confirmed the slope of the 
equation was equal to 1 (p < 0.001) and the intercept equal to 0 (Figure 4e). Indeed, the 
accuracy of the results with all doses was close to the 100% (Figure 4f).  
 
These results reveal that genipin-mediated fluorescence in GDP microcapsules is detectable 
even at low doses (50 µL is below the usually administered dose) (LLD = 18.6 µL) and 
reliably quantifiable from 100 µL and higher (LLQ = 59.6 µL). The ability to image GDP 
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fluorescence provides a powerful tool to immediately assess the quality of injection and then 
monitor stability of microcapsule signal over time with more than acceptable variability of 
measurements with usually administered doses (> 200 µL). Human errors we made and 
quantified in the present study are common in standard practice in the field of cell 
microencapsulation but undetectable without the technology described here. Therefore, GDP 
microcapsules represent a valuable tool to ensure correct administration of the intended dose 
and improve efficacy and biosafety of cell encapsulation therapies in the clinical routine.  
 
Unlike hydrogels with homogeneous cross-linking throughout their whole volume, GDP 
microcapsules, as cell-laden alginate microspheres with fluorescence limited to the external 
membranes (few microns), represent a demanding model for genipin-mediated in vivo 
imaging. This means that as capsule diameter increases, fluorescence signal related to a 
particular administered dose diminishes. Therefore, this visualization strategy will work much 
better when using particle sizes with high surface-area-to-volume ratio. Future studies will 
also reveal the feasibility of GDP capsule design for other usually used routes of 
administration, including intraperitoneal, intravitreal or intracranial.  
 
In summary, we present a multidisciplinary approach to develop implantable biosystems 
based on hydrogels with intrinsic fluorescence for in vivo imaging. In particular, we have 
shown that the use of genipin, an increasingly accepted cross-linker, functions as an excellent 
quantitative imaging probe to be included in the design of immunoisolation devices. Through 
this strategy, we have managed to visualize not only the location of the implanted 
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microcapsules, but also to evaluate the actual injected dose, which may improve significantly 
the efficacy and biosafety of the therapy. As fluorescence imaging systems are gradually 
implemented in clinical practice, we believe these outcomes will have direct applicability to 
advance design of multiple hydrogel-based biotechnologies, including drug and cell delivery 








Experimental Section  
All materials and methods used in this study are thoroughly detailed in the Supporting 
Information. 
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Figure 1. Optimization of genipin cross-linking procedure in cell-laden microcapsules. 
D1-MSC-hEPO enclosed within AP microcapsules were subjected to increasing genipin 
concentrations (0.001%, 0.01% and 0.1%) and exposure times (5, 15, 30 and 60 min) to find 
the optimum conditions.  a, Representative epi-fluorescence micrographs of each 
concentration and time combination. Scale-bar, 400 µm. b, Three-dimensional plot 
representing mean metabolic activity values of encapsulated cells in function of different 
genipin concentrations and exposure times. The white line indicates the mean value from non-
cross-linked AP control group. c, Three-dimensional plot representing mean fluorescence 
intensities of AP microcapsules in function of different genipin concentrations and exposure 
times. b,c, Color scale from light red to dark red denotes highest and lowest values, 
respectively. The white points depict the highest fluorescence signal intensities obtained 
without affecting cell viability (non-significant differences against cells encapsulated in non-
cross-linked AP microcapsules, p > 0.05). Statistical analysis: one-way ANOVA with 
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Bonferroni multiple comparison correction, n = 5 samples for each assay. d, Analysis of the 
conditions selected in (b,c) by means of confocal fluorescence microscopy. From left to right: 
representative confocal fluorescence micrographs, profile lines and 3D surface plots of the 
fluorescence signal distribution and intensity from the equatorial section of microcapsules. 






Figure 2. GDP microcapsules maximize the fluorescence of genipin while preserving cell 
viability and function.  a, Eschematic depiction showing GDP microcapsules and all the 
intermediate control groups assayed in the study. b, Reaction kinetics of genipin fluorescence 
development (Em: 590 nm; Ex: 630 nm) (n = 4 samples per group). Error bars, mean ±SD. c, 
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Fluorescence intensity of microcapsules 96 h after encapsulation (n = 4 samples per group). 
Error bars, mean ±SD. **, p < 0.01; ***, p < 0.001; One-way ANOVA with Tamhane 
multiple comparison correction. d, Confocal fluorescence analysis of microcapsules. From 
left to right: representative confocal fluorescence micrographs, profile lines and 3D surface 
plots of the fluorescence signal distribution and intensity from the equatorial section of 
microcapsules. Scale bar, 200 µm. e, Metabolic activity of encapsulated D1-MSC-hEPO cells 
(n = 4 samples per group) 96 h after encapsulation. Error bars, mean ±SD. N.S. specifies non-
significant differences against the AP group, p > 0.05; One-way ANOVA with Bonferroni 
multiple comparison correction. Mann–Whitney U test was used with APP group (non-normal 
distribution). f, Representative confocal fluorescence image of cells encapsulated in GDP 
microcapsules and probed with LIVE/DEAD viability kit (Green, living cells; Red, dead 
cells) 14 days after encapsulation. g, hEPO secretion of immobilized D1-MSC-hEPO cells (n 
= 3 samples per group in duplicate) 96 h after encapsulation. Error bars, mean ±SD. N.S. 
indicates non-significant differences against the AP group, p > 0.05; One-way ANOVA with 
Bonferroni multiple comparison correction. FL, fluorescence. 
 
This article is protected by copyright. All rights reserved.





Figure 3. GDP microcapsules maintain dose-dependent fluorescence over 35 days in 
vivo. a. White light image of 50, 100 and 200 µL of GDP microcapsules in 1.5 mL 
microcentrifuge tubes. b. Representative image of a mouse 21 days after injection of GDP 
microcapsules. We imaged fluorescence from the microcapsules with 570 nm excitation and 
620 nm emission.  Scale bar denotes range of photons displayed on a pseudocolor scale with 
yellow and dark red denoting highest and lowest values, respectively.  c, Graph displays dose-
dependent response of average radiant efficiency for GDP microcapsules.  Error bars, mean ± 
SD (n=4 per condition) d-g. Panels show representative fluorescence images of mice 1, 14, 21 
and 35 days after subcutaneous injection of microcapsules.  We used the same pseudocolor 
scale from panel (b) to display fluorescence.  h. Graph shows fluorescence of GDP 
microcapsules remained relatively constant over 35 days. Data are normalized to day 1 
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Figure 4. Analysis of obtained imaging data to validate genipin as a quantitative imaging 
probe. a. We monitored non-administered GDP microcapsules in parallel throughout 
experiment. Error bars, mean ±SD. N.S., non-significant (p > 0.05); Paired, two-tailed t-test, n 
= 5 independent experiments per time-point. b. Scatter plot of the Dose vs Radiant Efficiency 
showing the linear regression equation with 95% prediction interval. Each dot in the plot 
represents an individual measurement for each mouse, time point and dose. The linear 
correlation was confirmed by ANOVA (p < 0.001). The significance of the equation slope 
was statistically verified by means of the linear regression t-test. LLD, lower limit of 
detection. LLQ, lower limit of quantification. c. Variability of measurements taken at 
different time points for each dose (repeatability or instrument error). Error bars, mean ±SD. 
*, p < 0.05; One-way ANOVA with Bonferroni multiple comparison correction, n = 4 mice 
per dose. d. Variability of the injection procedure, reproducibility or human error expressed as 
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the dose calculated for each mouse and the CV of their mean. e. Scatter plot representing the 
Expected vs Obtained dose values. Each dot in the plot signifies an individual calculated 
value for each mouse, time point and dose. Colored area within dotted lines, 95% confidence 
interval. The linear correlation was tested by ANOVA (p < 0.001). The significance of the 
equation slope was statistically proven by a linear regression t-test. f. Accuracy of results for 
each particular dose expressed as error percentage. 
 
Genipin is incorporated into hydrogel-based immunoisolation devices as a quantitative 
imaging probe. Increasing doses of microcapsules are injected subcutaneously in mice, 
obtaining strong, stable fluorescence with good linearity of signal to microcapsule dose over 
several weeks. This allows immediate assessment of the actual injected dose and monitoring 





Genipin, quantitative imaging, biosafety, immunoisolation devices, hydrogels 
 
 
E. Santos-Vizcaino, H. Haley, A. Gonzalez-Pujana, G. Orive, R. M. Hernandez, G. D. Luker*, 
J. L. Pedraz* 
 
 












This article is protected by copyright. All rights reserved.

















Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2016. 
 
Supporting Information  
 
 
Monitoring Implantable Immunoisolation Devices with Intrinsic Fluorescence of 
Genipin 
 
Edorta Santos-Vizcaino, Henry Haley, Ainhoa Gonzalez-Pujana, Gorka Orive, Rosa Maria 







a. Cell culture 
Balb/c mouse-derived D1-MSCs (ATCC CRL12424) genetically engineered to secrete hEPO 
(D1-MSC-hEPO) were maintained in complete medium, consisting of: Dulbecco’s modified 
Eagle medium (DMEM) (ATCC 30−2002) supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin (P/S). Cells were seeded in T-flasks, grown at 37ºC in a 5% 
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CO2/95% atmosphere and passaged every 2-3 days. All reagents were purchased from Gibco 
(Life Technologies). 
b. Generation of D1-MSC-hEPO clone 
D1-MSC-hEPO clone was generated in the University Clinic of Navarra (CUN) with kind 
technical assistance from Dr Prosper’s group. Cells were transduced with the pSIN-EF2-Epo-
Pur lentiviral vector following the same procedure previously described by our group.[25] 
Briefly, the 293T packaging cell line (Clontech, Lenti-X™ 293T Cell Line, Cat. #632180) 
was transfected with 9 µg pSIN-EF2-Epo-Pur purified lentiviral vector, 3 µg of pMD2.G 
(Addgene plasmid 12259) and 6 µg of psPAX2 (Addgene plasmid 12260). Transfection was 
carried out by using 45 µL of lipofectamine® 2000 (Invitrogen, Carlsbad,CA,USA) according 
to manufacturer´s protocol. 72 hours after transfection, virus-containing culture supernatant 
from packaging cells together with 4 µg/mL of Polybrene (hexadimethrine bromide; Sigma, 
Cat. #H9268) were added to the D1-MSC cells. Successfully transduced cells were selected in 
complete medium containing 12.5 µg/mL of puromycin for 1 month. 
c. Encapsulation 
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Microcapsule matrices (beads) were produced by means of an electrostatic droplet generator 
(Nisco, Var V1).  Briefly, D1-MSC-hEPO cells were harvested from T-175 culture flasks 
using trypsin-EDTA (ThermoFisher Scientific, Cat. #25200056), filtered through a 40 µm 
pore mesh, centrifuged at 300 g and gently resuspended with a spatula in 1.5% sodium 
alginate (ProNova UP LVG, NovaMatrix, Cat. #4200006) at 5 x 106 cells/mL density. When 
empty capsules were used, this step was skipped. Thus, 1.5% alginate solution, with or 
without cells, was extruded through a 0.35mm needle using a single syringe infusion pump 
(KD Scientific, Cat. #78-9100) at a 5.9 mL/h flow rate. Electric potential difference between 
the needle tip and the gelling solution was kept at 8V. Dropped beads were collected in a 100 
mM CaCl2 gelling solution and maintained in agitation for 10 minutes to ensure complete 
ionic gelation. Beads were then washed and coated according to the following microcapsule 
design:  
AP: Classic alginate-poly-l-lysine microcapsules were obtained by suspending alginate beads 
in 0.05% PLL (Sigma-Aldrich, Cat. #P7890) solution for 5 minutes and subsequent washing 
with DPBS w/Ca++ and Mg++ (Lonza, Cat. #BE17-513F) to remove non-adhered polycation.  
APG: AP microcapsules were covalently cross-linked with 0.1% genipin (Wako, Cat. #078-
03021) for 5 minutes to form APG microcapsules, and then washed to remove unreacted 
cross-linker molecules.  
APP: AP microcapsules were coated with a second coating of PLL following the same 
procedure described above (0.05% PLL and 5 min exposure). 
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APGP: APG microcapsules with a second coating of PLL were obtained by suspending APG 
microcapsules in 0.05% PLL solution for 5 min followed by washing.  
GDP: APGP microcapsules were subjected to a second cross-linking reaction following the 
same conditions as above (0.1% genipin and 5 min exposure) to covalently bind the external 
PLL coating. Subsequently, unreacted genipin was washed away. 
All groups showed a quite similar particle-size (H 410 µm diameter) with narrow distribution 
(CV < 3%) (Figure S5). 
Considering electrostatic forces mainly mediate interactions between alginate matrix and PLL 
coating, we also discarded any possible effect of genipin cross-linking on the PLL net positive 
charge (See d. Zeta potential of PLL chains in solution).  Thus, we proved that genipin cross-
linking affects the positive charges of PLL chains only at 6 h (increasing) and 24 h (reducing) 
time points of the reaction, obtaining non-significant differences against PLL control upon 
completion of cross-linking (48 h) (Figure S6). 
All solutions described here were within physiological pH and osmolarity ranges as recently 
described  by our group.[26] The whole encapsulation process was carried out under aseptic 
conditions and at room temperature.  All resulting microcapsules were cultured in complete 
medium at 37ºC in a 5% CO2/95% air atmosphere.  
d. Zeta potential of PLL chains in solution 
Zeta potential of PLL chains in solution was measured by Laser Doppler Velocimetry (LDV) 
using a Zetasizer Nano ZS (Malvern Instrument). PLL and genipin were dissolved in 
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deionized water at a final concentration of 0.05% and 0.1% respectively. As a control PLL 
(0.05%) without genipin was used. Samples (100 µL) were diluted with 0.1 mM NaCl (900 
µL) and placed in a folded capillary cell for analysis. Zeta potential obtained from 
electrophorectic mobility was supported using the Smoluchowski approximation. Only data 
that passed the quality criteria stablished by the sofware DTS 5.0 were included in the 
analysis. Data is represented as mean ±SD of three independent samples. 
e. Optimization of genipin cross-linking procedure 
To determine optimum conditions for the cross-linking procedure, cells enclosed within AP 
microcapsules were subjected to increasing concentrations of genipin and exposure times.  
The final cross-linking procedure protocol was established on the basis of the highest 
fluorescence signal intensity obtained without affecting cell viability when compared to cells 
encapsulated in non-cross-linked AP microcapsules. 
f. Assessment of fluorescence signal intensity  
Fluorescence intensity was analyzed qualitatively by either epi-fluorescence microscopy 
(overall view) or confocal fluorescence microscopy (z-sectioning). For confocal images, 
profile lines and 3D surface plots of the equatorial section were built with ImageJ 1.49i 
(Wayne Rasband, National Institutes of Health, USA). For quantitative data, 65 
microcapsules-containing 100 µL of DPBS solution were pipetted per well (n=5) into a 96 
well black plate. Fluorescence signal intensity was measured at 590 nm excitation and 630 nm 
emission wavelengths using a Tecan Infinite M200 plate-reader based on excitation/emission 
spectra obtained previously (Supplementary Fig. 1) with GDP capsules under the same 
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conditions. For emission spectrum, GDP capsules were excited at 514 nm and emitted 
fluorescence was recorded from 550 to 700 nm. As for excitation spectrum, 500-650 nm 
range was scanned while reading the fluorescence emitted at 690 nm. In both cases, a step 
size of 2 nm was used. Obtained data are the mean of 4 replicates. 
 
 
g. Cell viability/Metabolic activity 
Metabolic activity of enclosed cells was assessed using CCK-8 cell viability kit (Sigma, Cat. 
#96992). Approximately 15,000 cells/well were plated in a 96 well plate. Then, 10 µL/well of 
CCK-8 were added. After 3 hours of incubation at 37ºC, the plate was read at 450 nm to 
measure colour development. Measured values were corrected with the reference wavelength 
at 690 nm and normalized against the mean value of 5 blank wells (medium). Results are 
expressed as the mean of 5 independent samples ±SD for every assay condition or study 
group. 
h. Live/Dead assay 
Encapsulated cells were dyed with the calcein-AM/ethidium homodimer-1 fluorescent probes 
of the LIVE/DEAD kit (Thermo Fisher Scientific, Cat. #L3224) according to the 
manufacturer’s indications. After 30 min of incubation at room temperature and protection 
from light, fluorescence micrographs were taken using a confocal fluorescence microscope 
(Leica TCS SP2 AOBS Spectral Confocal Scanner mounted on a Leica DM IRE2 inverted 
fluorescent microscope). The obtained micrographs were mounted in a z-stack using ImageJ.  
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i. Measurement of hEPO secretion  
Secretion of hEPO was measured in H135,000 encapsulated cells/well placed in 12 well plates 
with 1 mL medium. After a 24 hour release period, cell supernatants were assayed for hEPO 
secretion using the Quantikine IVD Human Erythropoietin ELISA Kit (R&D Systems, Cat. 
#DEP00). Standards and samples were run in duplicate as specified in the kit, and all results 
were expressed as the mean + SD of 3 independent experiments per study group.  
j. In vivo imaging 
To determine stability of imaging signal from genipin microcapsules in vivo, we implanted 50, 
100 or 200 µL of microcapsules subcutaneously into 15-week-old female NSG mice (n = 4 
per group). The University of Michigan IACUC approved all animal procedures. We 
implanted microcapsules through a 18G x 1¼ NIPRO SAFELET CATH (obtained from 
University of Michigan Hospital Pharmacy) into the dorsal region of each mouse. We imaged 
fluorescence from implanted microcapsules using 570 nm excitation and a 620/20 emission 
filter on an IVIS Spectrum (Perkin Elmer) as described previously.[27] To quantify imaging 
data, we measured radiant efficiency in defined regions-of-interest at each time point and then 
calculated mean values ± SD.  
k. Analysis of in vivo imaging data 
Background signal mean and SD were calculated from blank zones in mice at different time 
points (4 mice and 4 time points, n = 16). Lower limit of detection (LLD) and lower limit of 
quantification (LLQ) were calculated as follows: 
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LLD = (mean of background negative control radiant efficiency) + 3 x (SD of background 
negative control radiant efficiency).  
LLQ = (mean of background negative control radiant efficiency) + 10 x (SD of background 
negative control radiant efficiency). 
Variability of the technique, namely repeatability or instrumental error, was determined 
according to the mean of the coefficient of variation (CV) obtained from different 
measurements of the same dose at different time points (1, 14, 21 and 35 days) for each 
mouse. 
Variability of the injection procedure, reproducibility or human error (i.e. dose preparing and 
administration of microcapsules) was resolved for each dose.  The mean obtained from the 
same measurement along the four time points approximates the actual administered dose for 
each mouse, reducing data dispersion derived from instrumental error (repeatability). Then, 
the grand mean (mean of the means) of the four mice was calculated, from which the CV was 
considered as indicator of the injection procedure variability. 
The accuracy of results for each particular dose denotes the proximity of obtained values from 
expected ones, regardless of the dispersion resulting from either the instrument or human 
error. The mean from the same measurement along the four time points, whereby it is possible 
to obtain the nearest value of the actual administered dose for each mouse, was first calculated 
to minimize data dispersion derived from instrumental error (repeatability). Then, the grand 
mean (mean of the means) of the four mice was calculated to reduce variability caused by 
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human error. The resultant value was subtracted from the expected value and expressed as 
error percentage. 
l. Data analysis and statistics 
Results are shown as mean ±SD for line and dot graphs. The normal distribution of the data 
and homoscedasticity were checked by Shapiro-Wilk and Levene tests respectively. An 
unpaired, two-tailed t-test was used to detect statistical significances between two groups, 
while one-way ANOVA was used for multiple comparisons. In this case, Bonferroni or 
Tamhane post-hoc tests were applied depending on the obtained homogeneity of variances. 
When non-normally distributed data were observed, a Mann-Whitney non-parametric test was 
applied. Differences between means obtained within the same group along the time were 
probed using a paired, two-tailed t-test. Each figure caption specifies the sample size (n) and 
the statistical test used for each assay. p < 0.05 was considered statistically significant. All 
statistical computations were performed using SPSS 22 (IBM SPSS, Chicago, IL). *, p < 
0.05; **, p < 0.01; ***, p < 0.001.  
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Figure S1. Excitation and emission spectra of genipin cross-linked microcapsules. Emission 
spectrum, Ex: 514 nm / Em: 550-700 nm. Excitation spectrum, Ex: 500-650 nm / Em: 690 
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Figure S2. D1-MSC-EPO encapsulated in AP microcapsules and subjected to the genipin 
cross-linking protocols selected in Figure 1b,c. Non-cross-linked AP group was used as 
control. a, Metabolic activity of encapsulated cells after genipin cross-linking. Error bars, 
mean ±SD. N.S. non-significant differences; One-way ANOVA with Bonferroni multiple 
comparison correction, n = 5 per condition. b, Fluorescence intensity of AP microcapsules 
after genipin cross-linking. Error bars, mean ±SD. ***, p < 0.001; One-way ANOVA with 
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Figure S3.  Cross-linking reaction kinetics of GDP microcapsules and the intermediate 
control groups (n = 4). Linear least squares fitting method to demonstrate zero order (a) or 








This article is protected by copyright. All rights reserved.




Figure S4. Diameter size-dependent fluorescence intensity in GDP microcapsules. Error 









Figure S5. Diameters of GDP microcapsules and intermediate control groups (n = 15 
capsules per group). Boxes, interquartile range (Q1-Q3); Central point, median; Whiskers, 
max. and min. values.  
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Figure S6. a, Zeta potential of PLL chains in solution throughout genipin cross-linking 
reaction time-course. Error bars, mean ±SD. *, p < 0.05; **, p < 0.01; Unpaired, two-tailed t-
test, n = 3 per solution. b, Monitoring of the cross-linking reaction by means of genipin 
emitted fluorescence. Error bars, mean ±SD (smaller than markers). ***, p < 0.001; Unpaired, 
two-tailed t-test, n = 3 per solution. 
 
 
Video S1. 3D reconstruction using a stack of confocal images of GDP capsules to show its 
morphology. 
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Video S2. 3D reconstruction displaying fully viable cells (green) within GDP capsules (red). 
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